MCL Literature Feed

Comprehensive cfDNA analysis non-invasively tracks MCL disease burden and detects high-risk mutations, offering a powerful liquid biopsy tool for monitoring and risk stratification.

Nodal MCL with leukemic presentation is a high-risk subtype characterized by SOX11-negativity, increased TP53 alterations, and inferior overall survival, requiring distinct clinical consideration.

Real-world data on commercially insured B-cell NHL patients, including MCL, reveals a 48% relapse rate at 12 months post-CAR-T, with subsequent therapies incurring significant patient out-of-pocket costs.

Digital analysis of p53 immunohistochemistry establishes specific cut-offs (e.g., >50% for 2+/3+ nuclei) that reliably identify TP53 mutations and predict worse survival, improving rapid risk stratification.

This is the first study from North India providing real-world evidence that rituximab maintenance improves overall and event-free survival in MCL, validating this standard of care in an underrepresented population.

Retrospective data show B symptoms and CBV conditioning negatively impact survival post-ASCT in MCL, supporting BeEAM conditioning and risk-adapted strategies for consolidation.

This case series reports fatal Hepatitis B reactivation with ibrutinib and breakthrough reactivation on zanubrutinib despite prophylaxis, highlighting the need for vigilant HBV monitoring with all BTKis.

Korean real-world data confirms consolidative auto-SCT is effective, while in the relapsed setting, auto-SCT benefits chemosensitive patients and matched-donor allo-SCT is a viable option for refractory disease.

High NSD2 expression and specific mutations correlate with aggressive MCL variants, poorer treatment response, and inferior survival, establishing NSD2 as a key prognostic biomarker and potential therapeutic target.

Genomic analysis of MCL treated sequentially with BTKi and venetoclax identifies specific copy number alterations (e.g., 9p21.3 deletion) as novel biomarkers for primary and acquired resistance.

A commentary on a 40-year retrospective analysis confirms that therapeutic advances have led to gradual but significant improvements in overall survival for mantle cell lymphoma patients.

This Danish population-based study shows real-world ibrutinib outcomes (PFS 5.8 months) are inferior to clinical trials, with high-risk features and toxicity limiting efficacy, underscoring significant unmet needs.

The Endothelial Activation and Stress Index (EASIX) is a novel, independent prognostic biomarker in MCL, with high scores at diagnosis correlating with significantly shorter OS and PFS.

A four-decade analysis demonstrates significant, gradual overall survival improvement in MCL, validating the cumulative clinical impact of evolving therapies from chemotherapy to novel agents and transplant.

IGH/IGK gene rearrangement analysis improves diagnostic accuracy for B-cell lymphomas, with co-occurring IGH and IGK rearrangements being a characteristic feature of mantle cell lymphoma.

Polypharmacy independently predicts worse survival, hospitalization, and infection rates in lymphoid cancers, highlighting the critical need for medication reconciliation and management in the MCL population.

Real-world data on the ibrutinib, lenalidomide, and rituximab triplet in relapsed/refractory non-Hodgkin lymphoma provides practical insights into the efficacy and safety of this chemotherapy-free regimen.

A US claims analysis shows MCL treatment costs increase substantially with each line of therapy, driven by hospitalizations, underscoring the economic need for more effective, durable frontline regimens.

New prognostic scores, AMOS and AMES, were developed for Indian MCL patients, showing better predictive accuracy than MIPI using simple clinical factors for improved risk stratification.

This study identifies predictors of outcome for covalent BTKi therapy in relapsed/refractory TP53-mutant MCL, helping to risk-stratify patients and guide subsequent treatment decisions.

A targeted NGS panel characterized the mutational landscape of Korean lymphomas, including MCL, demonstrating its utility for identifying clinically relevant mutations like TP53 in diverse subtypes.

This large real-world analysis of elderly MCL patients shows improved first-line survival with modern therapies, but only modest survival gains after relapse, highlighting a critical unmet clinical need.

This paper describes the high frequency and characteristic patterns of gastrointestinal involvement in MCL, often as lymphomatous polyposis, highlighting the importance of endoscopy for accurate staging.

Hemoadsorption with CytoSorb safely reversed severe, refractory cytokine release syndrome in post-CAR-T patients, including one with MCL, offering a potential supportive strategy for managing life-threatening toxicities.

This paper likely characterizes the clinical features, treatment patterns, and poor outcomes of isolated central nervous system relapse in MCL, highlighting a major unmet clinical need.

The novel circular RNA-based biomarker, circSCORE, demonstrates prognostic value in relapsed/refractory MCL, offering a new tool for risk stratification in this high-risk patient population.

In a modern Canadian cohort, allogeneic transplant for relapsed/refractory MCL achieved a 5-year overall survival of 68.1%, confirming its ongoing relevance as a curative-intent therapy.

This retrospective series of six patients establishes that esophageal multiple lymphomatous polyposis in MCL signifies high tumor burden and a very poor prognosis, with median survival under two years.

In older relapsed/refractory MCL patients, brexucabtagene autoleucel offers superior 1-year overall survival and lower non-relapse mortality versus allogeneic transplant, though long-term outcomes are similar, guiding treatment selection.

In frontline MCL, pre-treatment ctDNA levels and TP53 mutations predict poor survival, while post-treatment ctDNA clearance identifies patients with favorable outcomes, establishing its clinical utility for prognosis.